17 Results for "

acute myeloid leukemia blasts

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "acute myeloid leukemia blasts" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-16271
CAS No.: 66592-89-0
Synonyms: 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18948
CAS No.: 1816331-63-1
Research Areas:  

Cancer

GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
Cat. No.: HY-P99971
CAS No.: 2924764-21-4

Research Areas:  

Cancer

Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-171792
Synonyms: ORM-6151
BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-108894
CAS No.: 722492-56-0
Purity:  95.00%
Ferumoxytol is an FDA-approved ultrasmall superparamagnetic iron oxide preparation and iron replacement agent that exerts selective activity against leukemia cells with low ferroportin expression. Ferumoxytol increases intracellular iron levels, induces reactive oxygen species (ROS) production via the Fenton reaction, and triggers oxidative stress and cell death. Ferumoxytol reduces disease burden in mouse models and patient-derived leukemia models. As an MRI contrast agent, Ferumoxytol enables imaging of vascular lesions, tumors and lymph nodes. Ferumoxytol can be used in research related to acute myeloid leukemia and blast-phase chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-128888B
CAS No.: 1816272-18-0
Purity:  98.62%
Research Areas:  

Cancer

(S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
Cat. No.: HY-P991665
Synonyms: OBT357NF; OBT357

Research Areas:  

Cancer

MEN1112 (OBT357NF; OBT357) is a defucosylated humanized monoclonal antibody targeting Bst1/CD157, with an EC50 of 0.4 nM. MEN1112 binds to Bst1/CD157 on acute myeloid leukemia cells, triggers slow antigen internalization, induces antibody-dependent cell-mediated cytotoxicity, and mediates the lysis of acute myeloid leukemia cells and blasts. MEN1112 is applicable for research related to acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-160952
CAS No.: 1256639-86-7
Synonyms: CPX 351; Cytarabine-daunorubicin
Research Areas:  

Cardiovascular Disease Cancer

Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .
loading...
    loading...
Cat. No.: HY-P991517
BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
loading...
    loading...
Cat. No.: HY-P990905
CAS No.: 2871775-98-1
Synonyms: SAR-443579

Target:  

Interleukin Related

Research Areas:  

Cancer

Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
loading...
    loading...
Cat. No.: HY-P991294

Target:  

ADC Antibodies

Research Areas:  

Cancer

MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
loading...
    loading...
Cat. No.: HY-P991425

Research Areas:  

Cardiovascular Disease Cancer

AT-1413 is a monoclonal antibody targeting CD43s that recognizes a unique sialylated CD43 epitope spanning amino acid residues 133-165. AT1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in AML cells, with EC50 values of 1.1 nM and 12.4 nM, respectively. AT-1413 binds to a variety of cancer cells, shows weak binding to non-malignant myeloid cells and endothelial cells, and does not bind to healthy lymphoid cells or normal non-hematopoietic cells. AT1413 clears CD43s-expressing leukemic blasts in vivo without affecting non-malignant myeloid cells. AT-1413 can be used in research related to acute myeloid leukemia, myelodysplastic syndrome, melanoma, and breast cancer .
loading...
    loading...
Cat. No.: HY-P992389

Target:  

LILRB

Research Areas:  

Cancer

IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .
loading...
    loading...
Cat. No.: HY-123113
CAS No.: 65886-71-7
Synonyms: Kymarabine; Ara-AC; NSC 281272
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Fazarabine (Kymarabine; Ara-AC; NSC 281272) is an orally active, blood-brain barrier permeable DNA polymerase inhibitor and antitumor agent. Fazarabine interferes with DNA synthesis via intracellular activation into a triphosphate nucleotide that directly incorporates into DNA, inducing cytotoxicity, myelosuppression, as well as moderate nausea and vomiting. Fazarabine is resistant to deamination by cytidine-deoxycytidine deaminase and undergoes spontaneous aqueous degradation. Fazarabine exerts time-dependent, broad-spectrum activity against leukemia and solid tumors. Fazarabine can be used in research related to refractory malignancies, acute leukemia, and blast-phase chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-123153
CAS No.: 1816331-64-2
Research Areas:  

Cancer

GSK990 is an inactive mutant IDH1 inhibitor with no significant inhibitory activity against wild-type or mutant IDH1/IDH2 enzymes. In experiments, GSK990 can serve as an inactive negative control for the IDH1 inhibitor GSK321 (HY-18948). GSK990 is applicable to the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-122670
CAS No.: 1627962-21-3
Research Areas:  

Cancer

VS-II-173 is a pan-Pim kinase inhibitor with IC50 values ​​of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations .
loading...
    loading...
Cat. No.: HY-124693
CAS No.: 869767-86-2
Target:  

Apoptosis

Research Areas:  

Cancer

DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity). DB1055 induces in vitro cell growth reduction, cell apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 leads to monocyte-to-macrophage differentiation and exhibits antileukemic activities in a human THP-1 AML in vivo model. DB1055 does not impact human CD34+ bone marrow cells. DB1055 can be used for the research of acute myeloid leukemia[1].
loading...
    loading...
  • 1